Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02003092
Title RX-5902 Treatment of Subjects With Solid Tumors
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Rexahn Pharmaceuticals, Inc.
Indications

triple-receptor negative breast cancer

Therapies

RX-5902

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.